Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation
- PMID: 22562960
- PMCID: PMC3598355
- DOI: 10.1093/gerona/gls138
Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation
Abstract
Background: Testosterone in Older Men with Mobility Limitations Trial found an increased incidence of cardiovascular events in men randomized to testosterone, resulting in enrollment cessation by trial's Data and Safety Monitoring Board. We evaluated changes in gonadal hormones and markers of inflammation and coagulation to elucidate risk factors associated with cardiovascular events.
Methods: Men aged 65 years or more, with mobility limitation, total testosterone 100-350 ng/dL, or free testosterone less than 50 pg/mL, were randomized to placebo or 10 g testosterone gel daily for 6 months. Changes in total and free testosterone, estradiol and estrone, C-reactive protein, interleukin 6, fibrinogen, plasminogen activator inhibitor-1, and pro-brain naturetic peptide were compared between groups and within the testosterone group between subjects who experienced cardiovascular events and those who did not.
Results: Of 209 men randomized (mean age 74 years), gonadal hormones and biomarkers were available in 179 men. Baseline body mass index, gonadal hormones, lipids, Framingham risk scores, and other biomarkers were similar in the two treatment groups. Within the testosterone group, the 6-month increase in free testosterone was significantly greater in men who experienced cardiovascular events than in those who did not [mean (95% confidence interval), 10.6 (4.6-16.7) vs 5.2 (3.0-7.5) ng/dL, p = .05]. In multivariable logistic regression analysis, the change in the serum levels of free testosterone was associated with cardiovascular events.
Conclusion: Mobility-limited older men who experienced cardiovascular events had greater increases in serum free testosterone levels than those who did not.
Figures
Similar articles
-
Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation.J Gerontol A Biol Sci Med Sci. 2011 Oct;66(10):1090-9. doi: 10.1093/gerona/glr100. Epub 2011 Jun 22. J Gerontol A Biol Sci Med Sci. 2011. PMID: 21697501 Free PMC article. Clinical Trial.
-
Low Plasma Testosterone Is Associated With Elevated Cardiovascular Disease Biomarkers.J Sex Med. 2017 Sep;14(9):1095-1103. doi: 10.1016/j.jsxm.2017.06.015. Epub 2017 Jul 27. J Sex Med. 2017. PMID: 28757119 Free PMC article.
-
Adverse events associated with testosterone administration.N Engl J Med. 2010 Jul 8;363(2):109-22. doi: 10.1056/NEJMoa1000485. Epub 2010 Jun 30. N Engl J Med. 2010. PMID: 20592293 Free PMC article. Clinical Trial.
-
Testosterone, aging and survival: biomarker or deficiency.Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):209-16. doi: 10.1097/MED.0000000000000057. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 24722173 Free PMC article. Review.
-
Hormones and cardiovascular disease in older men.J Am Med Dir Assoc. 2014 May;15(5):326-33. doi: 10.1016/j.jamda.2013.12.004. Epub 2014 Feb 12. J Am Med Dir Assoc. 2014. PMID: 24529874 Review.
Cited by
-
Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?Curr Treat Options Cardiovasc Med. 2016 Dec;18(12):75. doi: 10.1007/s11936-016-0496-0. Curr Treat Options Cardiovasc Med. 2016. PMID: 27807794 Review.
-
Comparative Safety of Testosterone Dosage Forms.JAMA Intern Med. 2015 Jul;175(7):1187-96. doi: 10.1001/jamainternmed.2015.1573. JAMA Intern Med. 2015. PMID: 25962056 Free PMC article.
-
The implications of low testosterone on mortality in men.Curr Sex Health Rep. 2014 Dec 1;6(4):235-243. doi: 10.1007/s11930-014-0030-x. Curr Sex Health Rep. 2014. PMID: 25685109 Free PMC article.
-
Effects of transdermal testosterone treatment on inflammatory markers in elderly males.Endocr Pract. 2014 Nov;20(11):1170-7. doi: 10.4158/EP13357.OR. Endocr Pract. 2014. PMID: 25100359 Free PMC article. Clinical Trial.
-
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.BMC Med. 2013 Apr 18;11:108. doi: 10.1186/1741-7015-11-108. BMC Med. 2013. PMID: 23597181 Free PMC article.
References
-
- The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA. 1970;214:1303–1313. - PubMed
-
- Hedlund PO, Johansson R, Damber JE, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol. 2011;45:346–353. - PubMed
-
- Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous